eli lilly clinical trials retatrutide Retatrutide, the next generation of GLP-1 drug from Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage trial, the company announced. In Retatrutide, Eli Lilly’s Next-Gen Obesity
Pay in 4 interest-free payments of $5.59 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3






























